Topical immunomodulators—progress towards treating inflammation, infection, and cancer
- 1 October 2001
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 1 (3), 189-198
- https://doi.org/10.1016/s1473-3099(01)00095-0
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot StudyThe Journal of Infectious Diseases, 2001
- Potentiating Effect of Imiquimod in the Treatment of Verrucae Vulgares in Immunocompromised PatientsPublished by Medical Journals Sweden AB ,2000
- Adjuvant Activities of Immune Response Modifier R-848: Comparison with CpG ODNCellular Immunology, 2000
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- CpG DNA rescues B cells from apoptosis by activating NFκB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathwayInternational Immunology, 1999
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- The Instructive Role of Innate Immunity in the Acquired Immune ResponseScience, 1996
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Interferon treatment enhances the expression of underphosphorylated (biologically-active) retinoblastoma protein in human papilloma virus-infected cells through the inhibitory TGFβ1/IFNβ cytokine pathwayAntiviral Research, 1994
- Papillomaviruses and human oncogenesisCurrent Opinion in Genetics & Development, 1992